DE69738754D1 - Hemmer der interaktion zwischen p53 und mdm2 - Google Patents
Hemmer der interaktion zwischen p53 und mdm2Info
- Publication number
- DE69738754D1 DE69738754D1 DE69738754T DE69738754T DE69738754D1 DE 69738754 D1 DE69738754 D1 DE 69738754D1 DE 69738754 T DE69738754 T DE 69738754T DE 69738754 T DE69738754 T DE 69738754T DE 69738754 D1 DE69738754 D1 DE 69738754D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- mdm2
- interaction
- human
- hemmer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title abstract 2
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 101001015963 Homo sapiens E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 102000055302 human MDM2 Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Amplifiers (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9614197.3A GB9614197D0 (de) | 1996-07-05 | 1996-07-05 | |
| GBGB9707041.1A GB9707041D0 (en) | 1997-04-07 | 1997-04-07 | Inhibitors of the interaction between p53 and mdm2 |
| PCT/EP1997/003549 WO1998001467A2 (en) | 1996-07-05 | 1997-07-04 | Inhibitors of the interaction between p53 and mdm2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69738754D1 true DE69738754D1 (de) | 2008-07-17 |
Family
ID=26309649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69738754T Expired - Fee Related DE69738754D1 (de) | 1996-07-05 | 1997-07-04 | Hemmer der interaktion zwischen p53 und mdm2 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0958305B1 (de) |
| JP (1) | JP2001500365A (de) |
| AT (1) | ATE397621T1 (de) |
| AU (1) | AU3847997A (de) |
| CA (1) | CA2259149A1 (de) |
| DE (1) | DE69738754D1 (de) |
| NZ (1) | NZ333609A (de) |
| WO (1) | WO1998001467A2 (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083983B2 (en) | 1996-07-05 | 2006-08-01 | Cancer Research Campaign Technology Limited | Inhibitors of the interaction between P53 and MDM2 |
| GB9708092D0 (en) * | 1997-04-22 | 1997-06-11 | Univ Dundee | Materials and methods relating to inhibiting the interaction of p53 and mdm2 |
| WO1998051707A1 (fr) * | 1997-05-15 | 1998-11-19 | Kyowa Hakko Kogyo Co., Ltd. | Peptides a structures cycliques et a effet restaurateur d'activite de la proteine p53 sur les mutants de ladite proteine |
| US6238921B1 (en) * | 1998-03-26 | 2001-05-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human mdm2 expression |
| EP0947494A1 (de) * | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Phenoxyessigsäure- und Phenoxymethyltetrazolderivate mit Antitumoraktivität |
| ATE283915T1 (de) * | 1998-05-26 | 2004-12-15 | Inst Of Molecul & Cell Biology | Polypeptide aus dem creb-bindenden protein und verwandten protein p-300 zur verwendung bei der transkriptionellen regulation |
| GB9819860D0 (en) | 1998-09-12 | 1998-11-04 | Zeneca Ltd | Chemical compounds |
| US7192713B1 (en) * | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| US20040038902A1 (en) * | 2000-04-05 | 2004-02-26 | Pincus Matthew R. | Peptides selectively lethal to malignant and transformed mammalian cells |
| AU2004212928A1 (en) | 2003-02-13 | 2004-09-02 | Bioveris Corporation | Deazaflavin compounds and methods of use thereof |
| WO2005044839A2 (en) | 2003-11-05 | 2005-05-19 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| US8598127B2 (en) * | 2004-04-06 | 2013-12-03 | Korea Research Institute Of Bioscience & Biotechnology | Peptides for inhibiting MDM2 function |
| AU2004319946A1 (en) * | 2004-04-22 | 2005-12-01 | 3-Dimensional Pharmaceuticals, Inc. | HDM2-inhibitor complexes and uses thereof |
| CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| KR101623985B1 (ko) | 2007-03-28 | 2016-05-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| JP2012515172A (ja) | 2009-01-14 | 2012-07-05 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
| EP2444105A4 (de) * | 2009-06-16 | 2013-08-21 | Univ Tokai | Anti-gram-negativer bakterieller wirkstoff |
| WO2011005219A1 (en) * | 2009-07-07 | 2011-01-13 | Agency For Science, Technology And Research | Novel mdm2 binding peptides and uses thereof |
| CA2771936A1 (en) | 2009-08-26 | 2011-03-03 | Novartis Ag | Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators |
| AU2010298338A1 (en) | 2009-09-22 | 2012-04-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| WO2012175487A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Cyclohexyl isoquinolinone compounds |
| WO2012175520A1 (en) | 2011-06-20 | 2012-12-27 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| CN108929375A (zh) | 2011-10-18 | 2018-12-04 | 爱勒让治疗公司 | 拟肽大环化合物 |
| MX351012B (es) * | 2011-11-09 | 2017-09-28 | Merz Pharma Gmbh & Co Kgaa | Neurotoxinas que exhiben actividad biologica acortada. |
| US9408885B2 (en) * | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| EP2819688A4 (de) | 2012-02-15 | 2015-10-28 | Aileron Therapeutics Inc | Triazol- und thioethervernetzte peptidomimetische makrozyklen |
| KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
| CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
| KR20150082307A (ko) | 2012-11-01 | 2015-07-15 | 에일러론 테라퓨틱스 인코포레이티드 | 이치환 아미노산 및 이의 제조 및 사용 방법 |
| US9403827B2 (en) | 2013-01-22 | 2016-08-02 | Novartis Ag | Substituted purinone compounds |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| EA029312B1 (ru) | 2013-05-27 | 2018-03-30 | Новартис Аг | Производные имидазопирролидинона и их применение при лечении заболеваний |
| KR20160012197A (ko) | 2013-05-28 | 2016-02-02 | 노파르티스 아게 | 피라졸로-피롤리딘-4-온 유도체 및 질환의 치료에서의 그의 용도 |
| MX2015016421A (es) | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
| AU2014351413B2 (en) | 2013-11-21 | 2017-06-01 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as BET inhibitors |
| SG10201902598VA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| CN106999541A (zh) | 2014-09-24 | 2017-08-01 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| MX2017011834A (es) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
| WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子 |
| ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
| WO2019118893A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
| WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN109206474A (zh) * | 2018-11-27 | 2019-01-15 | 青岛海洋生物医药研究院 | 一种线性肽合成方法 |
| US20220153868A1 (en) * | 2019-02-20 | 2022-05-19 | Oncolyze, Inc | Hdm2 antibody for use in treating cancer |
| CN112266407B (zh) * | 2020-09-28 | 2023-05-12 | 宁夏医科大学总医院 | 特异结合p53蛋白的七肽、编码基因、制备方法及用途 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
-
1997
- 1997-07-04 WO PCT/EP1997/003549 patent/WO1998001467A2/en not_active Ceased
- 1997-07-04 AU AU38479/97A patent/AU3847997A/en not_active Abandoned
- 1997-07-04 EP EP97935511A patent/EP0958305B1/de not_active Expired - Lifetime
- 1997-07-04 AT AT97935511T patent/ATE397621T1/de not_active IP Right Cessation
- 1997-07-04 CA CA002259149A patent/CA2259149A1/en not_active Abandoned
- 1997-07-04 DE DE69738754T patent/DE69738754D1/de not_active Expired - Fee Related
- 1997-07-04 JP JP10504775A patent/JP2001500365A/ja not_active Withdrawn
- 1997-07-04 NZ NZ333609A patent/NZ333609A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU3847997A (en) | 1998-02-02 |
| NZ333609A (en) | 2000-08-25 |
| EP0958305B1 (de) | 2008-06-04 |
| EP0958305A2 (de) | 1999-11-24 |
| ATE397621T1 (de) | 2008-06-15 |
| WO1998001467A2 (en) | 1998-01-15 |
| CA2259149A1 (en) | 1998-01-15 |
| JP2001500365A (ja) | 2001-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69738754D1 (de) | Hemmer der interaktion zwischen p53 und mdm2 | |
| UA39158C2 (uk) | Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі | |
| ATE186219T1 (de) | Kombination von antihormonale und bindende moleküle zur krebsbehandlung | |
| EA200000723A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
| ATE375362T1 (de) | Von cyclophilin b abstammende tumorantigen- peptide | |
| BR9907259A (pt) | Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso | |
| IL125590A (en) | Peptide immunogens, process for their preparation and use thereof as vaccines against allergies | |
| AU3804500A (en) | 2-amino-6-anilino-purines and their use as medicaments | |
| BR0009505A (pt) | Compostos e processos para terapia e diagnóstico de câncer de pulmão | |
| IL115517A0 (en) | Biologically active proteins | |
| GEP20043363B (en) | Indazole Compounds, Pharmaceutical Compositions, and Methods for Inhibiting Cell Proliferation | |
| PT848720E (pt) | Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros | |
| ATE197670T1 (de) | Parenterales busulfan zur behandlung von malignen krankheiten | |
| IL153680A0 (en) | Aplidine derivatives and methods for the preparation thereof | |
| RU95111308A (ru) | Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция | |
| HUT64569A (en) | A process for preparing polypeptide-type compounds usefules for medical treatment of the human body | |
| EA200500934A1 (ru) | Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний | |
| TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
| IL143516A0 (en) | COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B | |
| ATE310828T1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
| ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
| AU6987696A (en) | The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells | |
| NO901396L (no) | Fytosanitaere preparater, deres fremstilling og deres anvendelse for behandling av kryptogame sykdommer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |